Navigation Links
Sunesis Pharmaceuticals Presents Nonclinical Data on SNS-595 at the Annual Meeting of the American Association for Cancer Research
Date:4/14/2008

Nonclinical Studies Demonstrate that SNS-595 Acts through a Dual Mechanism

and May Evade Common Drug Resistance Mechanisms

Research Supports Current Clinical Development of SNS-595 in AML and

Ovarian Cancer and Potential in Additional Indications

SOUTH SAN FRANCISCO, Calif., April 14 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today presented nonclinical data on SNS-595's unique mechanism of action and its anticancer activity at the Annual Meeting of the American Association for Cancer Research (AACR) in San Diego, CA. A Phase 2 single agent clinical trial of SNS-595 in ovarian cancer and a Phase 1b clinical trial of SNS-595 in combination with cytarabine in relapsed/refractory acute myeloid leukemia (AML) are both ongoing.

"Data presented today provide important new insights into SNS-595's mechanism as a site-selective DNA intercalator and topoisomerase poison with selectivity for proliferating cells. Through its unique chemical structure and molecular mechanism, SNS-595 avoids common drug resistance pathways and may have advantages over other topoisomerase poisons," said Daniel C. Adelman, M.D., Senior Vice President, Development and Chief Medical Officer. "Taken together, these data support our ongoing clinical trials of SNS-595 in platinum-resistant ovarian cancer and acute myeloid leukemia, and provide compelling evidence for future studies of SNS-595 in indications such as breast cancer where topoisomerase II poisons are active."

Sunesis researchers conducted in vitro and cell-based studies elucidating SNS-595's mechanism of action. SNS-595 selectively intercalates DNA and poisons topoisomerase II, resulting in replication-dependent DNA damage, irreversi
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Sunesis Pharmaceuticals to Present at Healthcare Investor Conferences in March
2. Sunesis Pharmaceuticals SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology
3. Sunesis Pharmaceuticals Reports New Option Grants Under NASDAQ Marketplace Rule 4350
4. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
5. Alexion Pharmaceuticals Invites You to Participate in its First Quarter 2008 Results Conference Call and Web Cast
6. Access Pharmaceuticals to Present New Data on ProLindac(TM) at the AACR Annual Meeting 2008 Conference
7. ISTA Pharmaceuticals Announces Receipt of Subpoena Relating to Promotional Practices for XIBROM(TM)
8. Aida Pharmaceuticals, Inc. Announces New Antibiotic Drug Under Development
9. Bayer HealthCare Pharmaceuticals, Amerinet Extend Contrast Media Agreement
10. Idenix Pharmaceuticals to Present at the Canaccord Adams Hepatitis C Conference
11. Indevus Pharmaceuticals Licenses European Rights for VANTAS(R) to Orion Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... May 2008] Golf can be a good investment for the ... university Karolinska Institutet. The death rate for golfers is 40 ... sex, age and socioeconomic status, which correspond to a 5 ... are the safest. , It is a well-known fact ...
... Results from a pivotal Phase III clinical ... once-daily, investigational anticoagulant medication, was superior in preventing ... knee replacement (TKR) surgery. The head-to-head study compared ... the current standard of care. , Data from ...
... PRINCETON JUNCTION, N.J., May 30 Lutronic, Inc., ... medical laser systems,announced today that its MOSAIC eCO2 ... fractional technology with the deep,ablative features of a ... FDA review and,clearance., With intuitive touch-screen software, ...
... options, TORONTO, May 30 /PRNewswire-FirstCall/ - Predictive ... announced it has been notified by,the American Stock ... to,support PreMD,s plan for regaining compliance with the ... the Company,s common stock from the,Exchange by filing ...
... than white women to receive the radiation therapy routinely ... a study that Dana-Farber Cancer Institute researchers will present ... Clinical Oncology in Chicago. , Although the disparity in ... of black and Hispanic breast cancer patients may be ...
... Medical researchers at The Ohio State University, in ... million grant from the National Institutes of Health to ... that help identify and advance treatments for patients. The ... Ohio State. , The Ohio State University Center for ...
Cached Medicine News:Health News:Golf prolongs life 2Health News:Rivaroxaban phase III pivotal data presented at EFORT annual meeting 2Health News:Rivaroxaban phase III pivotal data presented at EFORT annual meeting 3Health News:Soon to Be Released: Lutronic Announces the MOSAIC eCO2, the World's First 'Smart' Fractional CO2 Laser System for Treating Aesthetic and Dermatological Conditions, Will Soon Be Coming to the U.S. Market for Commercial Use 2Health News:Soon to Be Released: Lutronic Announces the MOSAIC eCO2, the World's First 'Smart' Fractional CO2 Laser System for Treating Aesthetic and Dermatological Conditions, Will Soon Be Coming to the U.S. Market for Commercial Use 3Health News:Delisting Notification Received from the American Stock Exchange 2Health News:Blacks, Hispanics less likely than whites to receive follow-up radiation for early breast cancer 2Health News:Ohio State receives $34M NIH grant 2
(Date:12/24/2014)... -- Commonwealth Cornerstone Group (CCG) today announced the completion of an ... help fund the expansion and consolidation of healthcare services provided ... . PHN is the largest federally qualified ... is the largest employer in Sharon,s ... Currently, PHN Sharon offers scattered services out of ...
(Date:12/24/2014)... , Dec. 24, 2014 Kinex Pharmaceuticals ... with KX2-361 at Roswell Park Cancer Institute. ... molecule drug that has shown potent inhibitory activity against ... those that are resistant to Temozolomide (T98G), the most ... In a well-established brain tumor mouse model, KX2-361 consistently ...
(Date:12/24/2014)... 24, 2014  The International Trade Commission (ITC) issued its ... BMC Medical. In a notice issued on December 23, the ... patent on its humidifier was invalid. BMC President, ... "We are very excited with the ITC,s decision in this ... have taken since the very beginning on the key patents ...
Breaking Medicine Technology:Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 2Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 3Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2
... MOUNTAIN VIEW, Calif., Nov. 11 MAP Pharmaceuticals, Inc. (Nasdaq: ... at the Lazard Capital Markets 6th Annual Healthcare Conference on ... York City. , A live webcast of the presentation ... Pharmaceuticals, website at http://www.mappharma.com . A replay will also ...
... Finland, November 11 , ... be issued by the Finnish,Breast Cancer Group on Wednesday 11 November ... III Randomised Study in Women With Early Breast,Cancer Shows that Adding ... to Live Cancer-Free for Longer , An ...
Cached Medicine Technology:Landmark Study in The Lancet Oncology Shows Capecitabine (Xeloda(R)) Combination Therapy Reduces Early Breast Cancer Recurrence 2Landmark Study in The Lancet Oncology Shows Capecitabine (Xeloda(R)) Combination Therapy Reduces Early Breast Cancer Recurrence 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: